These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19734799)

  • 1. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.
    Varghese V; Shahriar R; Rhee SY; Liu T; Simen BB; Egholm M; Hanczaruk B; Blake LA; Gharizadeh B; Babrzadeh F; Bachmann MH; Fessel WJ; Shafer RW
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):309-15. PubMed ID: 19734799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
    Wang J; Zhang G; Bambara RA; Li D; Liang H; Wu H; Smith HM; Lowe NR; Demeter LM; Dykes C
    J Virol; 2011 Oct; 85(20):10861-73. PubMed ID: 21835788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
    Schiller DS; Youssef-Bessler M
    Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.
    Marcelin AG; Flandre P; Descamps D; Morand-Joubert L; Charpentier C; Izopet J; Trabaud MA; Saoudin H; Delaugerre C; Tamalet C; Cottalorda J; Bouvier-Alias M; Bettinger D; Dos Santos G; Ruffault A; Alloui C; Henquell C; Rogez S; Barin F; Signori-Schmuck A; Vallet S; Masquelier B; Calvez V;
    Antimicrob Agents Chemother; 2010 Jan; 54(1):72-7. PubMed ID: 19901096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
    Soulie C; Santoro MM; Storto A; Abdi B; Charpentier C; Armenia D; Jary A; Forbici F; Bertoli A; Gennari W; Andreoni M; Mussini C; Antinori A; Perno CF; Calvez V; Ceccherini-Silberstein F; Descamps D; Marcelin AG
    J Antimicrob Chemother; 2020 Apr; 75(4):1026-1030. PubMed ID: 31976534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Azijn H; Tirry I; Vingerhoets J; de Béthune MP; Kraus G; Boven K; Jochmans D; Van Craenenbroeck E; Picchio G; Rimsky LT
    Antimicrob Agents Chemother; 2010 Feb; 54(2):718-27. PubMed ID: 19933797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
    Halvas EK; Wiegand A; Boltz VF; Kearney M; Nissley D; Wantman M; Hammer SM; Palmer S; Vaida F; Coffin JM; Mellors JW
    J Infect Dis; 2010 Mar; 201(5):672-80. PubMed ID: 20102272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
    Bacheler LT; Anton ED; Kudish P; Baker D; Bunville J; Krakowski K; Bolling L; Aujay M; Wang XV; Ellis D; Becker MF; Lasut AL; George HJ; Spalding DR; Hollis G; Abremski K
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2475-84. PubMed ID: 10952598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
    Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
    AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
    Asahchop EL; Wainberg MA; Oliveira M; Xu H; Brenner BG; Moisi D; Ibanescu IR; Tremblay C
    AIDS; 2013 Mar; 27(6):879-887. PubMed ID: 23262501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.
    Agneskog E; Nowak P; Maijgren Steffensson C; Casadellà M; Noguera-Julian M; Paredes R; Källander CF; Sönnerborg A
    PLoS One; 2014; 9(7):e101508. PubMed ID: 25000302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
    Delviks-Frankenberry KA; Lengruber RB; Santos AF; Silveira JM; Soares MA; Kearney MF; Maldarelli F; Pathak VK
    Virology; 2013 Jan; 435(2):433-41. PubMed ID: 23068886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.